Compare Harmony Gold Mining Co. (HMY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harmony Gold Mining Co. vs Spyre Therapeutics Inc. Common Stock — how do they compare? Harmony Gold Mining Co. trades at $16.47 (market cap $10.37B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Harmony Gold Mining Co. is the larger of the two by market cap, and Harmony Gold Mining Co. pays a 4.67% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HMY | SYRE | |
|---|---|---|
Market Cap | $10.37B | $7.52B |
Volume | 2,951,252 | 1,441,031 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $108.92 |
52-Week Low | $13.32 | $22.18 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $10.42B | $6.52B |
Dividend Yield | 4.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HMY trades at $16.29, down 2.34% today, amid bearish technical signals but strong fundamentals. The stock shows robust revenue growth from $42.6B in 2022 to $73.9B in 2025, with net income surging to $14.4B. Valuation ratios remain attractive with P/E of 5.96 and EV/EBITDA of 3.64. Recent earnings showed mixed results with two beats and two misses in the last four quarters.
The outlook is cautiously optimistic given strong profitability metrics (ROE 46.23%, net margin 29.57%) and copper expansion plans, though technical weakness and analyst skepticism (70% hold rating) suggest near-term volatility. Key risks include gold price dependency and execution challenges in diversification efforts.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Harmony Gold Mining Co.
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
